arsenic has been researched along with etoposide in 22 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (9.09) | 18.2507 |
2000's | 10 (45.45) | 29.6817 |
2010's | 10 (45.45) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chrétien, P; Huot, J; Lambert, H; Landry, J; Roy, G | 1 |
Gallagher, RE; Huang, XJ; Klein, RS; Wiernik, PH | 1 |
Goker, E; Karabulut, B; Omay, SB; Sanli, UA; Sezgin, C; Terzioglu, E; Uslu, R | 1 |
Bruey, JM; Corcos, L; Garrido, C; Leroy, I; Lizard, G; Miguet, C; Plenchette, S; Rébé, C; Solary, E; Sordet, O | 1 |
Au, WY; Chim, CS; Chung, LP; Kwong, YL; Ma, SK | 1 |
Li, B; Lou, FD; Wang, YZ; Yao, SQ; Yu, L; Zhu, HL | 1 |
Bai, DC; Li, YN; Ma, LF; Peng, X; Wang, P; Wei, HL; Yao, XJ; Zhao, HS | 1 |
Mehta, J; Pichardo, D; Rosen, S; Singhal, S | 1 |
Karlsson, J; Påhlman, S; Pörn-Ares, I; Øra, I | 1 |
Guo, W; Tang, S; Tang, XD; Yang, Y | 1 |
Gokhalé, P; Morrison, MJ; Patel, T; Vissers, MC | 1 |
Aller, P; Calle, C; de Blas, E; Sánchez, Y | 1 |
Cao, F; Gilbert, GE; Heegaard, CW; Hou, J; Rasmussen, JT; Shi, J; Zhang, Y; Zhou, J | 1 |
Ayene, IS; Li, J; Prendergast, GC; Ward, KM; Zhang, D | 1 |
Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U | 1 |
Andersen, ME; Chen, Y; Dong, J; Fu, J; Hou, Y; Pi, J; Qu, W; Tokar, EJ; Waalkes, MP; Wang, A; Woods, CG; Xu, Y; Xue, P; Yarborough, K; Zhan, L; Zhang, H; Zhang, Q | 1 |
Beneytout, JL; Bertrand, J; Ghezali, L; Leger, DY; Liagre, B | 1 |
Fong, BM; Ho, JC; Lam, SK; Li, YY; Mak, JC; Zheng, CY | 1 |
Iland, HJ; Seymour, JF; Wei, A | 1 |
Boehme, KA; Handgretinger, R; Kluba, T; Nitsch, J; Riester, R; Schleicher, SB; Traub, F | 1 |
Chen, Z; Dai, Y; Gao, F; Guan, G; Liu, L; Ye, Y; Zhao, M; Zhao, P | 1 |
Fang, J; Guo, H; Li, Y; Liu, L; Qi, K; Xiong, X; Zhang, C | 1 |
2 review(s) available for arsenic and etoposide
Article | Year |
---|---|
Recent developments and future directions in the treatment of multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Clinical Trials as Topic; Cysteine Endopeptidases; Diphosphonates; Doxorubicin; Erythropoietin; Etoposide; Forecasting; Humans; Interferons; Multienzyme Complexes; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Oxides; Peripheral Blood Stem Cell Transplantation; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts | 2003 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin | 2014 |
20 other study(ies) available for arsenic and etoposide
Article | Year |
---|---|
Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein.
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenites; Blotting, Western; Carmustine; Cell Line; Cell Survival; Colchicine; Cricetinae; Dactinomycin; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Fluorouracil; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Pentosyltransferases; Sodium Compounds; Teniposide; Vincristine | 1991 |
Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Caspases; Enzyme Activation; Etoposide; Humans; Leukemia, Myeloid; Oxides; Signal Transduction; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1999 |
Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Butylated Hydroxyanisole; Carcinogens; Cisplatin; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Flow Cytometry; Humans; Male; Ovarian Neoplasms; Oxides; Prostatic Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2000 |
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Cell-Free System; Drug Resistance; Etoposide; Humans; Indazoles; Leukemia; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2; Tetradecanoylphorbol Acetate; U937 Cells | 2001 |
Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Mantle-Cell; Male; Neoplasms, Second Primary; Oxides; Pregnancy; Tretinoin | 2002 |
[The expression of Fas, FasL and Bcl-2 on RMA cells during the process of apoptosis induced by chemotherapeutic drugs].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Dexamethasone; Etoposide; Fas Ligand Protein; fas Receptor; Gene Expression; Membrane Glycoproteins; Mice; Oxides; Proto-Oncogene Proteins c-bcl-2; Tretinoin; Tumor Cells, Cultured | 2002 |
[Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; K562 Cells; Oxides | 2003 |
Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Calpain; Carboplatin; Caspase 3; Caspases; Cell Line, Tumor; Cytochromes c; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Mutation; Neuroblastoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Suppressor Protein p53; Vincristine | 2004 |
[Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Child; Etoposide; Female; Follow-Up Studies; Humans; Male; Osteosarcoma; Oxides; Paclitaxel; Sarcoma, Ewing; Treatment Outcome | 2006 |
The effect of intracellular ascorbate on the susceptibility of HL60 and Jurkat cells to chemotherapy agents.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Cell Count; Dehydroascorbic Acid; Drug Resistance, Neoplasm; Etoposide; HL-60 Cells; Humans; Jurkat Cells; Melphalan; Oxides | 2006 |
Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases.
Topics: Adamantane; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Catechin; Cell Cycle; Drug Synergism; Enzyme Activation; Estradiol; Etoposide; Genistein; HL-60 Cells; Humans; Hydroquinones; Immunoblotting; Microscopy, Fluorescence; Mitogen-Activated Protein Kinases; Oxides; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Small Interfering; U937 Cells | 2009 |
Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Blood Coagulation Tests; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Survival; Daunorubicin; Etoposide; Factor Xa; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Membrane Glycoproteins; Microscopy, Confocal; Milk Proteins; Oxides; Phosphatidylserines; Thrombin; Thromboplastin; Tretinoin; Young Adult | 2010 |
Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro.
Topics: Acetaminophen; Arsenicals; Arsenites; Biological Assay; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Disulfides; Ethanol; Etoposide; Humans; Hydrogen Peroxide; Hypoxia; Radiation, Ionizing; Toxicity Tests | 2012 |
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome | 2012 |
Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
Topics: Antineoplastic Agents; Antioxidant Response Elements; Arsenic Trioxide; Arsenicals; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation; Gene Knockdown Techniques; Glutamate-Cysteine Ligase; Heme Oxygenase-1; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Models, Biological; NAD(P)H Dehydrogenase (Quinone); Neoplastic Stem Cells; NF-E2-Related Factor 2; Oxides; PPAR gamma; Proto-Oncogene Mas; RNA Interference; Rosiglitazone; Thiazolidinediones | 2012 |
Cyclooxygenase-2 positively regulates Akt signalling and enhances survival of erythroleukemia cells exposed to anticancer agents.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Etoposide; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Erythroblastic, Acute; Oxides; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction; Staurosporine | 2013 |
Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; DNA Damage; Drug Synergism; Etoposide; Female; Glutathione; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mice; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxides; Reactive Oxygen Species; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2013 |
Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Neoplasms; Drug Synergism; Etoposide; Flow Cytometry; Humans; Oxides; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing; Tumor Cells, Cultured | 2016 |
[Influence of HMGB1/MAPK/m-TOR signaling pathway on cell autophagy and chemotherapy resistance in K562 cells].
Topics: AMP-Activated Protein Kinases; Arsenic Trioxide; Arsenicals; Autophagy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; HMGB1 Protein; Humans; K562 Cells; Microtubule-Associated Proteins; Oxides; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Vincristine | 2016 |
Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Neuroblastoma; Oxides | 2016 |